|Mr. Stephan Jackman||CEO & Director||473.12k||N/A||1976|
|Mr. Kenneth S. Cragun CPA||Sr. VP of Fin.||N/A||N/A||1961|
|Mr. David J. Katzoff||Chief Financial Officer||N/A||N/A||1962|
|Mr. Henry C. W. Nisser Esq.||Exec. VP, Gen. Counsel & Director||N/A||N/A||1969|
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.